2.34
1.30%
+0.03
Pre-market:
2.34
Lexaria Bioscience Corp stock is currently priced at $2.34, with a 24-hour trading volume of 460.96K.
It has seen a +1.30% increased in the last 24 hours and a -40.00% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $2.17 pivot point. If it approaches the $2.49 resistance level, significant changes may occur.
Lexaria Bioscience Corp Stock (LEXX) Financials Data
Lexaria Bioscience Corp (LEXX) Revenue 2024
LEXX reported a revenue (TTM) of $276.00 thousand for the quarter ending November 30, 2023, a -18.66% decline year-over-year.
Lexaria Bioscience Corp (LEXX) Net Income 2024
LEXX net income (TTM) was -$6.09 million for the quarter ending November 30, 2023, a +13.42% increase year-over-year.
Lexaria Bioscience Corp (LEXX) Cash Flow 2024
LEXX recorded a free cash flow (TTM) of -$5.99 million for the quarter ending November 30, 2023, a -17.14% decrease year-over-year.
Lexaria Bioscience Corp (LEXX) Earnings per Share 2024
LEXX earnings per share (TTM) was -$0.84 for the quarter ending November 30, 2023, a +30.00% growth year-over-year.
Lexaria Bioscience Corp Stock (LEXX) Latest News
Why Asana Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Benzinga
Lexaria Bioscience Corp. (NASDAQ: LEXX) Proprietary Drug-Delivery System Improves Way Molecules Enter Bloodstream
GlobeNewswire Inc.
Lexaria Bioscience Corp. (NASDAQ: LEXX) Improves Delivery, Efficacy of GLP-1 Agonists Through Proprietary Drug-Delivery Platform
GlobeNewswire Inc.
Lexaria Bioscience Corp. (NASDAQ: LEXX) Evaluating Proprietary Drug-Delivery Platform for Improved Efficacy of GLP-1 Drugs
GlobeNewswire Inc.
About Lexaria Bioscience Corp
Lexaria Bioscience Corp. operates as a biotechnology company. It operates through two segments, Intellectual Property Licensing and B2B Production. The company develops and out-licenses its DehydraTECH technology that improves the delivery of bioactive compounds that promotes healthy ingestion methods, lowers overall dosing, and higher effectiveness in active molecule delivery. Its DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, nicotine and its analogs, and various cannabinoids. DehydraTECH also deliver drugs effectively across the blood brain barrier. It operates a licensed in-house research laboratory and holds intellectual property portfolio with 27 patents granted and approximately 50 patents pending worldwide. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.
Cap:
|
Volume (24h):